Eurofins enhances its environmental, food and BioPharma product testing offering in Hungary through the acquisition of WESSLING Hungary

Eurofins Scientific (EUFI.PA), the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services, announces the completion of the acquisition of WESSLING Hungary.

WESSLING Hungary is one of the leading environmental, food and BioPharma product testing laboratories in Hungary, generating around €15m revenue in 2021 and employing over 300 staff. Located in Budapest, the company operates from a 11,000 m² modern building that also includes land reserved for future extensions. Its laboratories are equipped with state-of-the-art testing equipment and technology. The acquisition of WESSLING Hungary also further expands on Eurofins’ existing presence in the country, currently consisting of 5 laboratories in the fields of food, feed, environment, agro, and veterinary testing. This further reinforces Eurofins’ presence in Central and Eastern Europe and extends its position in BioPharma Product Testing.

WESSLING Hungary was established in 1992 by the WESSLING Group. Under the direction of Dr László Zanathy, it has since grown quickly to become one of the leading food, environmental and BioPharma product testing laboratories in Hungary.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Download Press Release as PDF